eligibility_summary
Eligibility: Adults (>=18) who consent, CD20+ B-cell lymphoma (DLBCL, FL, MCL, indolent to DLBCL), ECOG 0-1, >=1 measurable lesion (Lugano 2014), life expectancy >=3 mo, adequate labs, effective contraception. Exclude: inadequate washout, prior allogeneic cell/gene therapy (e.g., CAR-T, unless undetectable), allo-HSCT, or gene therapy, DSA+, severe comorbidities, HBV DNA/HCV RNA/HIV Ab+, other conditions per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: LUCAR-20SP, an allogeneic, gene-modified chimeric antigen receptor T‑cell (CAR‑T) therapy targeting CD20, for relapsed/refractory B‑cell non‑Hodgkin lymphoma. Mechanism: donor-derived T cells engineered with an anti‑CD20 CAR bind CD20 on malignant B cells, activating T‑cell effector functions (cytokine release, perforin/granzyme cytotoxicity) to eliminate CD20+ B cells. Preconditioning: cyclophosphamide (alkylating agent causing DNA crosslinks) and fludarabine (purine analog antimetabolite) provide lymphodepletion to enhance CAR‑T engraftment/expansion. Cells/pathways targeted: CD20 antigen on B cells in DLBCL, FL, MCL, and other indolent B‑cell NHL, T‑cell activation pathways, depletion of normal and malignant CD20+ B‑cell compartments via immune-mediated cytotoxicity.